Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2019

View Archived Issues

Cytokinetics presents additional analysis data from FORTITUDE-ALS study

FDA clears IND application for a phase I study of MV-012-968 vaccine for RSV

Positive topline data reported from phase II pozelimab in patients with PNH

Sage Therapeutics reports topline data from pivotal phase III MOUNTAIN study

Epigenetic reactivation of ADGRB3 as novel therapeutic strategy in WNT-medulloblastoma

ONC-201 demonstrates clinical efficacy in patients with thalamic H3 K27M-mutant glioma

The brain - silicone's new frontier?

CC-90009 shows antileukemic activity in patients with relapsed/refractory acute myeloid leukemia

Phase I/II trial of MERT with a CXCR4 inhibitor improves local control in glioblastoma

Safety and efficacy of SST2 antagonist [177Lu]-satoreotide tetraxetan in advanced SST2+ NET

AAV2 capsid fitness landscape allows systematic optimization of natural capsids for gene therapy

ASH 2019: Gene editing can move cell therapy from biplane to Boeing era

Preliminary data presented for TN-383B in patients with relapsed or refractory multiple myeloma

HitGen presents new IL-17RA antagonists

Synlogic begins phase I study of SYNB-1891 in advanced/metastatic solid tumors and lymphoma

Lilly initiates phase I/II study of LY-3499446 in advanced solid tumors with KRAS G12C mutation

Abbisko Therapeutics identifies FGFR inhibitors

Sunshine Lake Pharma discloses mineralocorticoid receptor antagonists

Js Innomed Holdings synthesizes new ERK2 inhibitors

GlaxoSmithKline identifies new NFE2-related factor 2 activators

New phase II trial investigates OQL-011 for hand-foot skin reaction in cancer patients

Phase III BE SURE study of bimekizumab in plaque psoriasis meets coprimary endpoints

Phase III PRIMROSE 2 trial of linzagolix for heavy menstrual bleeding meets endpoints

Partial clinical hold for pediatric patients in Ipsen's FOP and MO studies of palovarotene

Phase III study of nadofaragene firadenovec in bladder cancer meets primary endpoint